Gilead Hedges Against Eventual Generic Competition For Atripla With Bristol HIV Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
The two companies hope to repeat their Atripla success story by teaming up to develop a new combination drug for HIV containing Gilead's cobicistat and Bristol's atazanavir.
You may also be interested in...
Gilead/J&J NDA Could Mean Another Fixed-Dose Regimen For HIV
The pill combines J&J’s blockbuster protease inhibitor Prezista (duranavir) with Gilead’s boosting agent cobicistat. Currently, Prezista is required to be administered with the boosting agent ritonavir.
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.